Document is current
Any future updates will be listed below
-
Authors
Chockley, Peter J. https://orcid.org/0000-0002-5181-2696
Ibanez-Vega, Jorge https://orcid.org/0000-0003-4317-8573
Krenciute, Giedre https://orcid.org/0000-0003-4335-0644
Talbot, Lindsay J.
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
-
Funding
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (P30 CA021765)
Center for Strategic Scientific Initiatives, National Cancer Institute (R50 CA211481)
Center for Strategic Scientific Initiatives, National Cancer Institute (P30 CA021765)
Center for Strategic Scientific Initiatives, National Cancer Institute (P30 CA021765)
St Jude Sumara Fellowship
The Garwood Postdoctoral Fellowship
ChadTough Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS121249)
Rally Foundation
American Lebanese Syrian Associated Charities
- License Information
-
More Information
Article History
Received: 27 January 2022
Accepted: 16 December 2022
First Online: 2 February 2023
Competing interests
: S.G. and P.J.C. have patent applications in the fields of NK and T cell and/or gene therapy for cancer. S.G. has a research collaboration with TESSA Therapeutics, is a Data and Safety Monitoring Board member of Immatics and was on the scientific advisory board of Tidal. P.J.C. is a technical consultant for LUMICKS.
